Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14275MR)

This product GTTS-WQ14275MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14275MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2755MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ10699MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ6612MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ7384MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ10725MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ4442MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ6183MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ12966MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PDL 192
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW